Actipulse Neuroscience

Bringing neuromodulation treatment for depression, from the hospital to the home

Analytics

Raised to Date: Raised: $51,451

Aggregate Commitments $
Platform

Republic

Start Date

07/05/2021

Close Date

10/15/2021

Min. Goal

$25,000

Max. Goal

$1,070,000

Min. Investment

$100

Security Type

SAFE

Funding Type

RegCF

Series

Seed

Valuation Cap

$10,000,000

Discount Rate

0%

Rolling Commitments $
Status

Active

Reporting Date

07/29/2021

Days Remaining

78

% of Min. Goal

206%

% of Max. Goal

5%

Likelihood of Max
unlikely
Avg. Daily Raise

$2,144

# of Investors

109

Momentum
cold
Log in or create a free account today to gain access to KingsCrowd analytics.
Location

Cambridge, Massachusetts

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B2C

Margin

High

Capital Intensity

High

Business Type

Growth

Actipulse Neuroscience, with a $10 million valuation cap, is raising crowdfunding on Republic. The company has developed its proprietary neuromodulation medical device to treat the major depressive disorder in hospital settings. The business also aims to bring non-invasive treatment to patients’ homes. Adrien Chatillon founded Actipulse Neuroscience in June 2019. The current crowdfunding round has a minimum raise of $25,000 and a maximum raise of $1,070,000, and the funds will be used to expand the business beyond the US and the LATAM markets. Actipulse Neuroscience has generated $2 million in lifetime revenues and has been profitable since 2019. The hospital-setting devices generate $30,000 per end-user per year.
Summary Profit and Loss Statement
Most Recent Year Prior Year

Revenue

$248,406

$583,433

COGS

$6,267

$172,299

Tax

$33,720

$34,723

 

 

Net Income

$26,070

$79,323

Summary Balance Sheet
Most Recent Year Prior Year

Cash

$43,612

$22,189

Accounts Receivable

$182,624

$187,973

Total Assets

$438,383

$329,668

Short-Term Debt

$94,111

$184,420

Long-Term Debt

$172,654

$0

Total Liabilities

$266,765

$184,420

Financials as of: 07/05/2021
Log in or create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)

Starter

$8.33 /month
billed annually
Free portfolio tracking. Limited reports and filters.
Plan Includes:
Everything in Free, plus
Advanced company search ( limited filters)
Founder profiles and exclusive webinars
2 Analyst Reports per month
Get Starter Annual

Pro

$25 /month
billed annually
Unlimited analyst reports and market analytics.
Plan Includes:
Everything in Starter, plus
Full access to all Analyst Reports
Filter on Staff Picks (e.g. Top Deal, Deal to Watch, etc.)
Market Analytics
Get Pro Annual

Merlin

$41.67 /month
billed annually
Full site access including Merlin ratings.
Plan Includes:
Everything in Pro, plus
Search and filter companies by Merlin ratings
Company specific Merlin rating and risk assessment
Get Merlin Annual
Already a member? Log in here.

Ratings

Analyst Report

Other Deals

Cheers on StartEngine

Alcohol consumption is one of the oldest human practices on record. A study released in…

RegCF
EnGen Bio on Wefunder

COVID-19 has brought the world’s attention to vaccine development. In April 2021, a record 4

RegCF
Audubon Bioscience on MicroVentures

In 2020 alone, companies produced, tested, and began to produce a vaccine for a completely new virus on…

RegCF
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Actipulse Neuroscience on Republic 2021
Follow company
Follow Actipulse Neuroscience on Republic 2021
Want to learn more about Actipulse Neuroscience?
Join the Pre-IPO Market’s #1 Ratings & Analytics Service FREE for 7 days.
Yes! I want to start my free trial.
Already a member? Log in here.
Invest Now